Related Experiment Video
Updated: Jan 9, 2026
Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
Novel Molecular Subtyping Predicts Locoregional Recurrence in Triple-negative Breast Cancer
Shali Shao1,2,3, Wei Shi4,5,6,7, Li Zhang4,5,6,7
1Department of Radiation Oncology, Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
Purpose:
Immunohistochemistry (IHC)-based molecular subtyping provides a comprehensive profile of triple-negative breast cancer (TNBC). We aimed to elucidate patterns of locoregional recurrence (LRR) in different subtypes of TNBC.
Methods And Materials:
In this study, 352 patients with breast cancer treated with mastectomy and postmastectomy radiation therapy from November 2019 to March 2022 were retrospectively analyzed. Based on IHC, these patients were classified into the basal-like immune-suppressed (BLIS) and non-BLIS groups. We compared LRR as the first event, disease-free survival, and overall survival (OS) between the 2 groups. Univariate and multivariate analysis was performed.
Results:
The median follow-up time was 44.6 months. Twenty-six LRR (including 9 isolated LRR) and 70 distant metastases (DMs) were observed. The cumulative incidence of LRR was significantly different between the 2 groups, with an LRR rate of 5.8% in the non-BLIS group and 14.9% in the BLIS group (P = .005). The difference in OS was also significant (91.9% vs 83.0%, P = .01). However, there was no significant difference in disease-free survival between the non-BLIS and BLIS groups (80.2% vs 74.5%, P = .35). Multivariate analysis demonstrated that IHC-based molecular subtyping was an independently prognostic factor for LRR and OS (P = .03; P = .03).
Conclusions:
This study demonstrated that the BLIS subtype appears to be at a higher risk of developing LRR, and IHC-based molecular subtyping might be used as prognostic biomarkers to guide postmastectomy radiation therapy in patients with TNBC. New strategies that improve locoregional control rates in patients with BLIS are warranted.
